Eye implant offers new hope

Article

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

The CentraSight treatment programme features a small telescope implant for patients with binocular end stage AMD. This treatment has, until now, only been available in the US and is the only surgical option that has been clinically proven to improve visual quality and quality in life for patients at this stage of the disease.

Mr Ahmed El-Amir, consultant ophthalmologist at Spire Dunedin, Reading, UK, was the first surgeon to perform the procedure in the UK. “I am very pleased to be able to offer my patients this revolutionary treatment, which is a true paradigm shift for patients with untreatable, advanced AMD who have had, up to now, very limited options in improving their quality of life,” he said.

Another surgeon who has recently performed a CentraSight procedure, Mr Nick Wilson-Holt (Duchy Hospital, Truro, UK) added, “CentraSight is a clinical programme that is very carefully targeted only to suitable patients who will potentially gain visual acuity from the procedure. It is not a cure for end-stage AMD, but it allows patients to use the undamaged part of their central retina to be able to see or discern objects using portions of their central vision once more.”

More detailed information about the procedure and its availability may be found on the website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.